Silgan (SLGN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Q1 2026 net sales reached $1.56 billion, up 6.4% year-over-year, driven by higher raw material pass-throughs, favorable FX, and strong growth in fragrance/beauty and pet food packaging, partially offset by lower volumes in other segments and less favorable mix.
Net income was $63.0 million ($0.60 per diluted share), down from $68.0 million ($0.63 per diluted share) in Q1 2025, reflecting margin contraction and higher costs.
Adjusted net income per diluted share was $0.78, compared to $0.82 in the prior year, impacted by lower EBIT and higher tax rate.
Double-digit organic volume growth was achieved in fragrance/beauty dispensing and pet food metal containers, with the Weener integration driving innovation.
Gross profit margin declined to 17.0% from 18.4% year-over-year, reflecting less favorable mix and higher inventory costs.
Financial highlights
Adjusted EBIT was $152.0 million, down from $158.3 million in Q1 2025, with segment performance mixed and higher corporate expense.
Adjusted EBIT margin for Q1 was approximately 9.5%.
Cash used in operating activities was $799.6 million, compared to $683.4 million in the prior year, with capital expenditures of $82.4 million.
Dividends paid were $22.8 million, with $0.21 per share declared.
Adjusted EBITDA for Q1 2026 was $220.8 million.
Outlook and guidance
Full-year 2026 adjusted EPS guidance raised to $3.73–$3.93, exceeding prior record levels at the low end.
Q2 2026 adjusted EPS expected at $0.92–$1.02 vs. $1.01 prior year; Q2 interest expense guided at $50 million, tax rate 25–26%.
Free cash flow for 2026 estimated at $450 million, with CapEx of $310 million.
Management expects sufficient liquidity from operations and credit facilities to meet obligations and capital allocation needs.
Ongoing evaluation of acquisition opportunities in consumer goods packaging.
Latest events from Silgan
- Proxy covers director elections, incentive plan amendment, auditor ratification, and say-on-pay.SLGN
Proxy filing16 Apr 2026 - Record 2025 growth in key segments, with further earnings and cash flow gains expected in 2026.SLGN
Q4 20254 Feb 2026 - €838M acquisition expands dispensing leadership, targets €20M synergies and 10% EPS accretion.SLGN
M&A Announcement3 Feb 2026 - Q2 net sales fell 3.2% to $1.38B, but gross margin and adjusted EPS both increased.SLGN
Q2 20242 Feb 2026 - Q3 2024 saw record dispensing growth and Weener acquisition, setting up strong 2025 prospects.SLGN
Q3 202417 Jan 2026 - Record Q4 results and 2025 double-digit growth outlook driven by acquisitions and dispensing demand.SLGN
Q4 20249 Jan 2026 - Record Q1 2025 sales and earnings growth driven by Weener acquisition and volume gains.SLGN
Q1 202524 Dec 2025 - Proxy covers director elections, auditor ratification, say-on-pay, and strong governance.SLGN
Proxy Filing1 Dec 2025 - Record Q2 sales, 15% EPS growth, and strong outlook despite $20M EBIT headwinds.SLGN
Q2 202516 Nov 2025